433 Eli Lilly and Company $LLY Shares Acquired by Principle Wealth Partners LLC

Principle Wealth Partners LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 3.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,354 shares of the company’s stock after acquiring an additional 433 shares during the quarter. Principle Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $14,295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of LLY. Bank of America Corp DE bought a new stake in Eli Lilly and Company in the second quarter worth $13,522,666,000. Jupiter Topco LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at $4,667,180,000. Fifth Third Bancorp raised its stake in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Corient Private Wealth LP bought a new position in Eli Lilly and Company during the second quarter valued at $764,116,000. Finally, BlackRock Inc. lifted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,500 shares of company stock worth $17,020,770. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Up 0.5%

LLY traded up $7.42 during trading on Friday, reaching $1,372.15. The company had a trading volume of 3,802,992 shares, compared to its average volume of 2,624,130. The stock has a market cap of $1.29 trillion, a P/E ratio of 44.54, a PEG ratio of 1.77 and a beta of 0.40. The business has a 50 day simple moving average of $1,215.24 and a 200-day simple moving average of $1,101.16. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,453.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the business posted $7.02 earnings per share. The business’s revenue was up 38.6% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Analyst Ratings Changes

A number of equities analysts have commented on LLY shares. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, October 30th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Royal Bank Of Canada lifted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Finally, Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,404.14.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.